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Key Messages
n Evidence suggests the demographic age structure
of sub-Saharan Africa is the leading factor of the low
morbidity and mortality of COVID-19 compared to
other regions of the world.
n Widespread social mitigation strategies, such as
lockdowns, have resulted in severe economic and
societal consequences in terms of food security,
adolescent pregnancy, gender-based violence, and
disruptions in treating other diseases.
n It is imperative to weigh the risks and benefits of
social mitigation strategies for future waves.
ABSTRACT
The burden of coronavirus disease (COVID-19) in sub-Saharan
Africa (SSA) has been substantially lower compared to other
regions of the world. Extensive morbidity and mortality were not
observed among countries in SSA during the first wave of the
COVID-19 pandemic. To explain this phenomenon, several hy-
potheses have been formulated, including the low median age
of the population in most SSA countries, lack of long-term care
facilities, cross-protection from other local coronaviruses, insuffi-
cient testing and reporting resulting in an undercounting of
COVID-related deaths, genetic risk factors, or the benefit of early
lockdowns that were extensive in many SSA countries. Early lock-
downs in SSA have been some of the strictest and resulted in dev-
astating economic and social consequences and increased
mortality from other health-related problems including maternal
deaths. We review the literature and rationale supporting the
various hypotheses that have been put forward to account for rel-
atively low hospitalization and death rates for COVID-19 in SSA.
We conclude that the strongest evidence would support the de-
mographic age structure with a very low median age as the pri-
mary factor in leading to the low mortality seen in the first wave
of the pandemic. The impact of new variants of concern in SSA
raises the risk of more severe waves. Nevertheless, furthering the
understanding of the underlying explanations for the low morbid-
ity and mortality seen across SSA countries may allow the adop-
tion of unique strategies for limiting the spread of COVID-19
without the need for stringent lockdowns.
BACKGROUND
COVID-19 has impacted the world immensely sinceits discovery in the city of Wuhan, China, in
December 2019.1,2 As of June 27, 2021, approximately
181.9 million COVID-19 cases have been confirmed
with more than 3.9 million deaths.3 COVID-19 has dra-
matically impacted the Americas, Europe, and Asia. As
of June 27, 2021, in the Americas, 73.1 million con-
firmed COVID-19 cases with 1.9 million deaths have
been reported, 47.8 million confirmed cases with more
than 1 million deaths in Europe, and 55.4 million con-
firmed cases with 784,965 deaths in Asia.4
The impact ofCOVID-19 inAfricahas been substantial-
ly lower compared to countries in the Americas, Europe,
and Asia. The World Health Organization (WHO) African
Region reported more than 3.9 million confirmed cases
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and 94,217 deaths, as of June 27, 2021.5 Moreover,
the mortality rate of COVID-19 per million in Africa
is considerably lower than in all otherWHO regions
other than the Western Pacific (Table 1).5–11 Public
health preparedness is a significant aspect in the suc-
cess of reducing COVID-19 transmission. Lessons
learned from countries across Eastern Asia imply
theneed for community-oriented strategies and rap-
id response from public health officials to successful-
ly contain the COVID-19 pandemic.12 Strategies
such as early case identification, widespread labora-
tory testing and screening, outbreak mitigation (up
to and including lockdowns), contact tracing, health
education, physical distancing, and quarantinemea-
sures have been demonstrated as essential interven-
tions in curbing the pandemic.
This article critically examines the hypotheses
that have been attributed to the apparently lower
than expected morbidity and mortality of COVID-
19 in SSA to help guide public health decision
making regarding essential interventions for con-
taining COVID-19.
POTENTIAL MITIGATING FACTORS
INFLUENCING THE MORBIDITY AND
MORTALITY OF COVID-19 IN SUB-
SAHARAN AFRICA
It is posited that the low impact of COVID-19 in
SSA is due to 1 or several of 6 main hypotheses
(Figure 1).
Hypothesis 1: Demographics of sub-Saharan
Africa
Global mortality trends of COVID-19 showmarked
differences by demographic characteristics includ-
ing age (increased risk of severe illness in older
individuals), sex (higher among males), socioeco-
nomic status, and race (higher among Blacks).
In the United States, the Centers for Disease
Control and Prevention (CDC) report that 80%
of COVID-19-related deaths occur in individ-
uals aged 65 years and older.13,14 Data from
the United Kingdom has demonstrated that the
strongest risk for death is advanced age, which
dramatically outweighs the risks associated with any
other demographic factor or medical condition.15
Demographic structures for Europe, the Americas,
and Asia demonstrate median age ranges from
32 years to 42.5 years,4,16–19 with 8.9% to 19.1% of
the population older than 65 years.20–23
In contrast, the median age of the SSA popula-
tion is considerably lower, with a median age of
18 and only 3.0% of the African population older
than 65 years.24,25 Figure 2 compares the popula-
tion pyramids of Uganda and Canada, which are
similar in overall population size. The median age
of Canada (41.1 years) is remarkedly higher than
that of Uganda (16.7 years).26,27 In Uganda, less
than 0.2% of the population is in the highest-risk
group of developing more severe illness (aged
80 years and older).28 Conversely, the proportion
of individuals aged 80 years and older in Canada is
higher (4.4%).29 Further, Figure 3 illustrates the
distribution of COVID-related deaths in Canada
as of June 25, 2021.30 A large proportion of deaths
are attributed to older age; approximately 98.0%
of COVID-related deaths occur in individuals
aged 50 years and older, with approximately
64.7% in individuals aged 80 years and older.30
With the rollout of COVID-19 vaccinations and
prioritization of those aged 70 years and older in
North America and other areas, the mean age of
those being admitted to hospital has de-
creased.31,32 However, it is still highly likely that
TABLE. Confirmed COVID-19 Cases and Mortality Rates per WHO Regiona
WHO Regionb COVID-19 Cases COVID-Related Deaths Populationc Mortality Rate per Million
Africa5 3,942,448 94,217 1,019,922,000 92.4
Americas6 71,959,063 1,891,291 992,155,000 1,906.2
South-east Asia7 34,657,785 485,398 1,947,632,000 249.2
Europe8 55,821,905 1,181,992 916,315,000 1,289.9
Eastern Mediterranean9 10,916,353 215,799 664,336,000 324.8
Western Pacific10 3,521,244 54,069 1,889,901,000 28.6
Abbreviations: COVID, coronavirus disease; WHO, World Health Organization.
a Information up to date as of June 27, 2021.
b Refer to the Supplement for a comprehensive list of WHO Member States.
c Population data taken from the 2016 WHO Global Health Observatory data repository.11
Lessons learned
from Eastern Asia
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those aged 70 years and older remain the highest
risk among the unvaccinated population.
Comparisonof the age demographics ofUganda
with other lower-middle-income countries in
regions such as Latin America and the Caribbean
and South Asia demonstrates the uniqueness of
the demographic structure in SSA. The median
age in Brazil is 33.5 years, Peru 31.5 years, and
Mexico 29.2 years, which are all markedly higher
than in SSA. Low-income countries in Latin
America and the Caribbean, such as Nicaragua, El
Salvador, and Haiti also have greater median ages
FIGURE 1. Proposed Hypotheses Explaining the Limited Impact of COVID-19 in SSA
Abbreviations: COVID-19, coronavirus disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SSA, sub-Saharan Africa.
FIGURE 2. Population Pyramids of Uganda and Canada28,29
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(24.0–27.6 years) and a larger proportion of the
population age 65 and older (5.2%–8.7%) than in
SSA.33–38 Similar demographics are observed for
countries in South Asia, such as India and
Pakistan; median age ranges from 22.8–28.4 years
with 4.4%–6.6% of the population aged older
than 65 years.39–42
Older age is associated withmore degenerative
and metabolic disorders that have also been
shown to heighten the risk of death from COVID-
19. Therefore, it is posited that the demographic
structure of SSA plays a critical role in the low
morbidity and mortality of COVID-19. It is possi-
ble that the burden of severe disease and death
may be low despite suspected and undetected
widespread transmission. In fact, it is possible that
widespread transmission has already occurred
without precipitating the high death rates seen
elsewhere due to the relatively small proportion
of elderly and lack of large long-term care facilities
for the elderly, which have been the epicenters of
mortality in Canada and elsewhere.43 It is notable
that some areas of SSA, such as South Africa, have
a much higher median age (27.6 years), which
could be a reason for the higher COVID-19 death
rates seen there.44
Hypothesis 2: Lack of Long-Term Care
Facilities
In addition to the demographic pyramid demon-
strating very low numbers of elderly, the elderly in
SSA do not tend to live in long-term care facilities.
The CDC defines long-term care facilities as those
whereby elderly who are unable to live independent-
ly receivemedical and personal care.45Unfortunately,
long-term care facilities pose a significant risk for in-
fectious and communicable diseases; approximately
1.0–3.0 million infections occur in these facilities per
year.45,46 During the first wave of the epidemic in
Canada, 81.0% of all deaths occurred in long-term
care facilities.47Transmission to theelderly canbepar-
ticularly efficient in these settings and lead to amark-
edly higher infection fatality rate.48
Across SSA, long-term care facilities are almost
nonexistent, with the notable exception of South
Africa, leaving the provision of care to families.49,50
Large young families with high levels of unemploy-
ment and low labor costs enable care to be provided
by individual relatives rather than a team of profes-
sionals, which limits the number of caregivers that
may transmit infection. In the first wave, approxi-
mately33%ofSouthAfrican long-termcare facilities
experienced outbreaks.51 Furthermore, data from
South Africa have demonstrated that COVID-19-
related deaths are highly correlated with increased
age; approximately 2.2% of all COVID-19-related
deaths occurred among persons younger than
30 years, despite their consisting of 54.2% of the
population.52,53 This is a further potential explana-
tion for South Africa being an outlier with a higher
death rate than in other African countries.54
Hypothesis 3: Prior Exposure to Coronavirus
Infection
In addition to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that
FIGURE 3. Age Distribution of COVID-19 Cases Deceased in Canada as of June 25, 202130
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causes COVID-19, 6 other human coronaviruses
have been identified. Seasonal human corona-
viruses, such as NL6, 229E, OC43, and HKU1, are
common and result in cold- or flu-like symp-
toms.55 Zoonotic coronaviruses, such as Middle
East Respiratory Syndrome (MERS)-CoV and
SARS-CoV, are responsible for more severe dis-
eases.55 Previous exposure to locally circulating co-
ronaviruses and the development of antibodies is
posited to mediate cross-protection to COVID-19
and induce partial immunity.56
Several studies have been conducted to inves-
tigate this unique relationship. Studies assessing
antibody prevalence to SARS-CoV-2 in pre-
pandemic serum samples observed a significant
increase in the prevalence of cross-reactivity
among sera in SSA compared to other con-
tinents.57 In addition, previous studies have
demonstrated high false positivity when testing
pre-pandemic sera from SSA using European
assays.58,59 The discrepancy of seropositivity may
be attributed to widespread exposure to various
endemic coronaviruses before the emergence of
the SARS-CoV-2 pandemic. A limitation of these
studies was the use of serological assays to deter-
mine previous exposure, particularly because
there can be discrepancies in results when com-
paring T-cell versus antibody evidence of expo-
sure and immunity.60 In contrast, a study by
Sagar et al.61 used results from previously per-
formed comprehensive respiratory panel poly-
merase chain reaction assays to examine the
impact of previous exposure to endemic corona-
viruses in COVID-19 patients. Their results dem-
onstrated a significant decrease in odds of
mortality and odds of being admitted to an inten-
sive care unit in patients who had evidence for
previous exposure to endemic coronaviruses com-
pared to those who did not.56,61 These findings in-
dicate that exposure to other coronaviruses may
reduce the severity and burden of COVID-19.
Furthermore, a recent study by Uyoga et al.62 ob-
served increased rates of antibody prevalence to
SARS-CoV-2 among Kenyan blood donors be-
tween April 30–June 16, 2020, that are higher
than case counts would predict.
Hypothesis 4: Limited Access to Adequate
Testing
There are concerns regarding the recording of
COVID-19 cases in SSA. It is hypothesized that
there has been a dramatic undercounting of
deaths due to lack of SARS-CoV-2 testing as was
suggested in the mass media to have happened in
Kano, Nigeria.63,64 Current data may not reflect
the true extent of the disease. The true numbers
of infected and deaths could be higher given that,
at least in South Africa where the median age is
much higher than SSA as a whole,44 the excess
mortality observed is far higher than the officially
reported totals for deaths from COVID-19. Lack of
local access to testing and contact tracing, and in-
sufficient data collection have interfered with the
ascertainment of the incidence and prevalence of
COVID-19 in SSA. The WHO reports varying
levels of testing across Africa, however, testing is
still relatively low compared to other areas of the
world.65 As of June 25, 2021, testing rates ranged
from as low as 7.7 tests per 1,000 population in
Madagascar to as high as 215.3 and 389.9 tests
per 1,000 in SouthAfrica andGabon, respectively.66
However, these numbers are far lower than rates in
the United States (1,401.8 tests per 1,000 popula-
tion) and the United Kingdom (2,973.0 tests per
1,000population).66Although low testing rates like-
ly resulted in amuch lower case rate, the lack of hos-
pital overcrowding and widespread deaths likely
resulted from lower morbidity and mortality in this
region. This would suggest a lower predisposition to
severe illness. The initial priority for the Africa Task
Force for Novel Coronavirus was to expand COVID-
19 testing capability. This expansion proceeded rap-
idly; at the outset of the pandemic, only 2 labs in
Africa were capable of SARS-CoV-2 detection, but
by mid-March 2020, 43 countries had this laborato-
ry capability.67 Preliminary observations from the
poorly maintained civil and vital registration sys-
tems seem to indicate that it is unlikely that there
has been excess all-cause mortality in the region.68
Studies are underway in Kenya assessing excess
mortality through verbal autopsies and population-
based serosurveys for past infections to assess past
exposure.69
The concerns of recording the impact of COVID-
19 across SSA offers the opportunity of novel means
of data collection to expand current knowledge on
COVID-19 morbidity and mortality. Morbidity may
be further explored through the use and purchase of
oxygen as a proxy of the current situation in hospi-
tals. Further, data collection on death may be ex-
tended to churches and faith groups, obituaries,
and morticians. These and other means should be
further explored to help better understand the im-
pact of COVID-19 on SSA as a whole.
Hypothesis 5: Genetic Risk Factors
Studies from developed countries have demonstrat-
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including those of African or South Asian descent.15
This predisposition is likely related to socioeconomic
factors including poverty, crowding, andworking in
essential services. Therefore, overall environmental
exposures are likely farmore important than genetic
exposures in disease susceptibility.
Hypothesis 6: Effective Government Public
Health Response to COVID-19 Threat
Another hypothesis is that African governments
and public health organizations moved remark-
ably swiftly in response to the threat of COVID-
19. Early in January 2020, African governments
began to plan for the arrival of COVID-19 as high
flight volumes between China and Africa pre-
dicted early spread to multiple locations including
South Africa, Nigeria, and Kenya.70 As early as
January 2, 2020, Côte d’Ivoire implemented en-
hanced screening measures for passengers arriv-
ing from China.71 Other African countries swiftly
followed suit. In February 2020, the first meeting
of the newly established Africa Task Force for
Novel Coronavirus convened. The first confirmed
case of COVID-19 on the African continent was
reported in Egypt on February 14, 2020, and
linked to travel from China. By March, almost
all African nations had suspended flights from
China. After March 2020, most cases imported to
Africa originated from Europe, as the epicenter of
the disease had shifted there.72 By May 2020,
more than 40African nations had closed their bor-
ders to all but cargo.71
National public health institutions are respon-
sible for disease surveillance, diagnostics, and rap-
id response to outbreaks, making them essential
for curbing the emergence and re-emergence
of infectious diseases in the African context,
especially COVID-19.73 As of 2019, Botswana,
Ethiopia, Ghana, Liberia, Morocco, Mozambique,
Namibia, Nigeria, Rwanda, Sierra Leone, South
Africa, Uganda, and Zambia all had highly func-
tional national public health institutions with ex-
perience in battling infectious diseases.73,74 These
organizations focus on infectious disease threats,
which is in contrast to those organizations in
high-income countries that have focused on non-
communicable diseases. Uganda is a leading ex-
ample of curbing the impact of COVID-19 in the
African context. Rapid response and implementa-
tion of risk communication, testing, social and
physical distancing measures, and contract tracing
were critical for the success seen in Uganda.75
Additionally, new programs to promote re-
gional sharing of COVID-related information
were initiated across SSA. For example, the East
African Community created the Regional
Electronic Cargo and Drivers Tracking System.
This system electronically shares the COVID test
results of truck drivers between member countries.
In addition, the programuses the drivers’ cell phones
to track their routes and record stops. This tracking
allows for quick contact tracing in the event of a
COVID-19 outbreak.76 Furthermore, several African
countries have scored particularlywell in critical pol-
icy areas in terms of public health directives, financial
responses, and fact-based public communications to
help control COVID-19.77 In particular, Kenya,
Ghana, and Ethiopia scored more than 95 on a
100-point scale.77 This may have helped to mitigate
the scope of the pandemic although further valida-
tion of the scores would be helpful.
Other Hypotheses
Adherence to Preventative Strategies
Some studies suggest that adherence to recommen-
dations for handwashing, social distancing, andpub-
lic masking has been widespread in SSA,78,79
however, the generalizability of these observations
to multiple SSA countries and contexts, as well as
comparative data between African and non-African
countries require further study.
Drugs Against Parasitic Infections
Infections with parasites have been suggested to
be associated with less severe COVID-19 in an as
yet non-peer-reviewed Ethiopian study although
this finding requires replication in other locales.80
SSA countries within the tropical and equatorial
regions appear to have the lowest proportion of
confirmed COVID-19 cases and the highest bur-
den of malaria infection.81 Several factors have
been posited to contribute to the low incidence of
COVID-19 in these malaria-endemic countries,
including cross-protection from consistent use of
antimalarial medication.81 However, the failure
of hydroxychloroquine to prevent COVID-19 in
randomized studies makes this hypothesis less
likely.82 In addition, ivermectin, an antiparasitic
drug used to treat several neglected tropical dis-
eases, such as onchocerciasis, strongyloidiasis,
and lymphatic filaria,83,84 has been widely used
across SSA since the 1990s.85 A study conducted
by Caly et al.86 found ivermectin to be an inhibitor
of the SARS-CoV-2 virus in vitro. Despite the hy-
pothesized association between antiparasitic med-
ications and COVID-19, at present, there is still
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Prevalence of Noncommunicable Diseases
Noncommunicable diseases, such as hyperten-
sion, diabetes, and obesity, have been observed to
increase the severity of COVID-19 illness.89 In
comparison to North America, the rates of non-
communicable diseases, such as diabetes and obe-
sity, are remarkedly lower in SSA. Data from 2017
demonstrate that the prevalence of diabetes in the
United States and Canada was observed to be
10.8% and 7.4%, respectively.90 Conversely, the
prevalence of diabetes among SSA was observed
to range from 1.0%–7.8%, with exception of
Sudan and South Sudan, whereby the prevalence
of diabetes was 15.7% and 10.4%, respectively.90
Further, approximately 70.2% and 67.5% of
adults in the United States and Canada, respec-
tively, have been observed to be either overweight
or obese (BMI greater than 25).91 Conversely,
among countries in SSA, these rates range from
18.1%–38.4%, with exception of South Africa
whereby 51.9% of adults are either overweight
or obese.91 The prevalence of hypertension, how-
ever, is considerably higher in SSA compared to
North America.92 Further studies should be con-
ducted to understand the roles of noncommunic-
able diseases and COVID-19 severity in the
African context.
Mobility
It also has been hypothesized that lower mobility
and spending a greater amount of time outdoors
may have reduced the risk of COVID-19, especial-
ly in impoverished rural areas.93 Reduced travel
between African countries due to limited visa-
free relationships may have also limited spread
across the continent.94 Further study would be
necessary to confirm these hypotheses.
SOUTH AFRICA AS AN OUTLIER
South Africa appears to have had a particularly
high incidence of COVID-19 hospitalizations and
deaths. This has been attributed to several phe-
nomena. As noted above, South Africa has a
higher median age as well as an established long-
term care facility sector. The very high HIV and
TB burden in South Africa may be another factor
as both of these were found to be associated with
an increased COVID-19 mortality rate in a South
African cohort.54 Maintaining antiretroviral ther-
apy is particularly important in light of the data
demonstrating poor COVID-19 outcomes in
patients with low CD4 counts.95 In addition, the
effects of noncommunicable diseases may contrib-
ute to the higher burden of COVID-19 seen in
South Africa. The prevalence of hypertension in
South Africa has been reported to range from
26.9%–30.4% and is increasing.96,97 Furthermore,
the prevalence of diabetes in South Africa has been
reported to be 12.8%98 andwas found to be the sec-
ond leading cause of death in South Africa in
2015.99 Moreover, obesity rates among men and
women in South Africa have been reported to be
31.0% and 68.0%, respectively. Further research
needs to be conducted on various noncommunic-
able factors that may contribute to the increased
COVID-19 burden seen in South Africa.
Better diagnostics and health care documenta-
tion, including death registries, may also allow for
higher reporting rates. The emergence of the
SARS-CoV-2 variant, 501.V2, has demonstrated
the potential for greater transmissibility and risk
of reinfection as well as a concern of relative vac-
cine resistance, leading to severe future waves of
infection in South Africa.100,101
IMPLICATIONS FOR POLICIES AND
PROGRAMS
Based on the current COVID-19 situation in SSA, to
help policy makers and programs improve health
practice, the following policy prescriptions have
emerged:
 Reduce emphasis on lockdowns, which may
disproportionately affect young people and the
poor and may lead to other severe health con-
sequences as noted in the article.
 Emphasize the importance of good governance re-
gardinghealth directives andopen communication.
 Provide financial support to vulnerable sectors
as per experience in Kenya and Ghana.77 In
light of the limited resources of many African
countries, this may require the assistance of ex-
ternal agencies.
 Prioritize an international effort to develop vac-
cines tailored to the SARS-CoV-2, 501.V2.
 The impact of oxygen shortages in a developing
country suffering a COVID-19 outbreak has been
severely apparent in India.102,103 Therefore, gov-
ernments must ensure the availability of medical
infrastructure should an unexpected rapid
system-wide severe outbreak occur.
 Prioritize efforts to establish molecular epide-
miology to be aware of the emergence of new
variants. In particular, the emergence of new
variants of concern, which may be more viru-
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reconsideration of Africa’s susceptibility to a se-
vere epidemic.
 Conduct studies to determine the risk factors
for severe disease in the African context. These
may include detailed cohort studies of patients
who do get severely ill in SSA countries with
appropriate controls (such as patients who test
negative for SARS-CoV-2).
CONCLUSIONS
In reviewing the totality of the evidence, we be-
lieve that it is suggested that in SSA the overall
death rate is lower than in most other regions pri-
marily due to the demographic structure with a
low median age and a small percentage of vulner-
able elderly, although as noted, other factors likely
also play a role. Some localized areas with a great-
er number of older individuals, such as South
Africa, may be exceptions to this trend. The pres-
ence of a long-term care facility sector as well as
extremely high rates of HIV and TB coinfection,
and effects of noncommunicable diseases may
also have led to South Africa having a higher dis-
ease burden. Limited resources for disease diagno-
sis, effective public health campaigns, and other
factors discussed are also important considera-
tions. Further studies to clarify these various hy-
potheses for the low mortality presently reported
in Africa are required. While data accrue, the risks
and benefits of widespread social mitigation strat-
egies such as lockdowns, need careful consider-
ation. The continent is reeling from the effects of
the pandemic; the economic and societal tolls in
terms of hunger, teen pregnancy, gender-based
violence, and disruptions in the treatment of ma-
laria, TB, and HIV are enormous. Furthermore,
the 501.V2 variant of SARS-CoV-2 heightens the
risks of further waves and raises the risk to the
rest of the continent, including the danger of hos-
pitals reaching capacity in other SSA countries.104
However, as discussed, widespread adoption of
stringent lockdown strategies used previously
should be undertaken only with great caution.
Consideration must be given to local, unique con-
ditions such as the age structure of the population,
competing health risks, and food security.104
With the recent experience of a severe second
wave in India, it is imperative to establish ade-
quate molecular epidemiology to monitor emerg-
ing variants that have the potential to cause severe
infection in the younger population. As full vac-
cine rollout in Africa with widespread coverage
will likely not occur for some time, these issues re-
main of critical importance. This review of the
literaturewill aid countries in adopting unique strat-
egies for limiting the spread of COVID-19 without
the need for stringent lockdowns. Further research
on the potential mechanisms needs to be carried
out to understand other possible reasons for the ob-
served discrepancy in mortality seen in SSA.
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